‘Only a few patients with metastatic melanoma with the BRAF V600 mutation have a response to systemic chemotherapy in addition most of the median survival time have only six to 10 months, however, showed that study an overall response rate of 56 % and a median survival time of almost ‘ ‘.
According to the researchers from the USA and Australia, including researchers at Moffitt Cancer Center in Tampa, Florida, about 50 percent of the study participants had positive responses and a prolonged median survival time of nearly 16 months.. Authors and effective for some patients with metastatic melanomaresults from a Phase II multicenter clinical study with 132 patients metastatic with previously treated BRAF V600 mutant melanoma that vemurafenib – an oral BRAF inhibitor – a high rate of offered reaction in some patients.‘It is indeed a little disturbing and humbling experience in order to, through a list of previous winners the then new prestigious nephrology appear that I admired and I am still admiring greatly. Me low the feeling that of you of you as of Francophone renal Community equal deserve as much or longer this honor first and foremost primarily to French School of kidney specialist. I am very proud this distinction on behalf and well as in that out of the numerous fellows and staff, fostered nurtured our research project accepts accept at the past 30 years.